Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Solicitation / RFP / RFQ

This document is a Request for Quotation (RFQ) from the Department of War (DOW) for pharmaceutical agents to be placed on the Uniform Formulary (UF). The DOW is establishing an effective and efficient pharmacy benefits program for the Military Health System (MHS) as required by law. Manufacturers have the opportunity to submit offers that reduce DOW's cost for consideration by the Pharmacy and Therapeutics (P&T) Committee.

• The solicitation seeks quotes for pharmaceutical agents for inclusion on the UF, potentially leading to UF Blanket Purchase Agreements (UF BPA) and UF Additional Discount Program (UF ADP) Agreements.

• Quotes must include pricing for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP) via UF BPA, and refunds for TRICARE retail network pharmacies via UF ADP.

• Pricing must be TAA compliant, unless an exception is granted.

• Companies must be registered in SAM.gov.

• Quotes must include a National Drug Code (NDC) Price List.

• The document outlines two primary instruments: UF BPA for MTF and TMOP, and UF ADP for retail network refunds.

• UF BPA price quotes are valid for 180 days.

• UF ADP refund quotes are contingent upon the agent being placed on the UF (generic or formulary tier).

• Key Dates:

  • Posting Date: June 8, 2026
  • Pre-Quotation Teleconference: June 10, 2026
  • Quotes Due: June 29, 2026
  • Responses to Clinical Questions Due: June 29, 2026
  • P&T Committee Meeting: August 5-6, 2026

• Submission Steps: Download utilization dataset and NDC Price List, complete applicable pages and appendices, and submit signed quote(s) and NDC Price List to the RFQ Point of Contact.

• Evaluation: The P&T Committee will consider clinical effectiveness and cost-effectiveness, including UF BPA price quotes and UF ADP refund quotes, when recommending placement on the UF and determining cost share tiers.

• No specific set-aside is mentioned. However, Trade Agreement Act (TAA) compliance is required for any potential Government award.

• A pre-quotation teleconference and one-on-one appointments with the Industry Technical Liaison are available.

• The document includes detailed definitions, acronyms, and specific instructions for submitting UF BPA and UF ADP quotes.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for atypical antipsychotic agents. It includes a Blanket Purchase Agreement (BPA) Appendix and two Additional Discount Program (ADP) Appendices (one for non-FAMP discounts and one for WAC discounts). These documents outline pricing structures, potential discounts, and requirements for manufacturers responding to the opportunity.

• BPA Appendix: Lists Uniform Formulary (UF) and Non-Formulary (NF) scenarios for atypical antipsychotic agents, with a "Quotes due" date of June 29, 2026. It specifies that pricing is per NDC, per unit, and includes notes on class reviews, prior authorization, and potential special reimbursement methods.
• ADP (non-FAMP Discount) Appendix: Details pricing and refund calculations based on non-Federal Ceiling Price (FCP) for atypical antipsychotic agents. It outlines scenarios for Tier 2 and Tier 3 drugs and includes a "Quotes due" date of June 29, 2026.
• ADP (WAC Discount) Appendix: Outlines pricing and refund calculations based on Wholesale Acquisition Cost (WAC) for atypical antipsychotic agents. It also includes scenarios for Tier 2 and Tier 3 drugs and a "Quotes due" date of June 29, 2026.
• General Notes: All appendices mention that the P&T Committee Meeting is scheduled for August 5-6, 2026. Manufacturers are reminded to submit the Quote Review Checklist and fully executed signature pages. The documents also contain class notes regarding potential Prior Authorization (PA) and Step Therapy.

This document is critical for bidders interested in supplying atypical antipsychotic agents. It provides the specific pricing structures (BPA, non-FAMP, WAC), discount mechanisms, and deadlines (June 29, 2026) for submitting quotes. Understanding these pricing appendices is essential for preparing a competitive proposal.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for antiretroviral combination drugs, intended for the August 2026 P&T Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) with non-FAMP and WAC discounts, and associated formulary scenarios.

• BPA Appendix: Lists NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing per unit for antiretroviral combination drugs. It specifies "NO QUOTE" for certain formulary scenarios and includes notes regarding Prior Authorization and Step Therapy.
• ADP (non-FAMP Discount) Appendix: Details pricing and refund calculations based on non-Federal Acquisition Regulation (non-FAMP) prices and Federal Ceiling Prices (FCP). It outlines refund formulas and requires manufacturers to submit a Quote Review Checklist and executed signature pages.
• ADP (WAC Discount) Appendix: Outlines pricing and refund calculations based on Wholesale Acquisition Cost (WAC). It specifies that WAC is used for products without an FCP and details the calculation of total retail refunds.
• Common Information: All appendices share a quote due date of June 29, 2026, and reference the August 5-6, 2026 P&T Committee Meeting. Class notes regarding Prior Authorization and Step Therapy apply across the board.

This document is crucial for bidders offering antiretroviral combination drugs. It provides the framework for pricing, discount structures (non-FAMP and WAC), and refund calculations. Bidders must review the specific formulary scenarios, pricing requirements, and submission instructions (including the Quote Review Checklist and signature pages) to prepare accurate quotes by the June 29, 2026 deadline. The document also highlights potential pricing considerations such as Prior Authorization and Step Therapy.

Forms / Attachments / Pricing Sheets

This document contains pricing information and appendices related to the Uniform Formulary (UF) Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Antiemetic-Antivertigo Agents. It outlines pricing structures and discount programs relevant to potential vendors.

• BPA Appendix: Details the Uniform Formulary (UF) Blanket Purchase Agreement for Antiemetic-Antivertigo Agents. It includes sections for "Formulary Scenarios" with columns for NDC Number, Drug Name, Strength, Dosage Form, Package Size, and pricing per NDC, package size, and unit. It specifies "NO QUOTE" for certain scenarios and indicates that cells highlighted red require confirmation of intent not to submit a quote.
• ADP (non-FAMP Discount) Appendix: Outlines the Additional Discount Program (ADP) for Antiemetic-Antivertigo Agents, focusing on non-FAMP (Federal Ceiling Price) discounts. It details calculations for "Total Calculated Refund Per FCP" and includes columns for NDC Number, Drug Name, Strength, Dosage Form, Package Size, and various pricing and refund metrics.
• ADP (WAC Discount) Appendix: Details the ADP for Antiemetic-Antivertigo Agents using Wholesale Acquisition Cost (WAC) discounts. It includes columns for NDC Number, Drug Name, Strength, Dosage Form, Package Size, WAC Price of Drug, WAC Discount, and Total Calculated Retail Refund per Package.
• Class Notes: Applicable to all sections, these notes indicate that agents will be reviewed by the P&T Committee, Prior Authorization (PA) may apply, and agents may be subject to special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. A Step Therapy Addendum notes that agents without submitted or selected RFQs may be designated non-step preferred.
• Notes to Manufacturers: Reminds manufacturers to submit the Quote Review Checklist and fully executed signature pages along with quote information.

This document is crucial for bidders as it provides the framework for pricing and discount submissions for Antiemetic-Antivertigo Agents. It specifies the due date for quotes (2026-06-29) and outlines the required pricing structures (BPA, non-FAMP ADP, WAC ADP) and associated calculations. Bidders must understand these pricing requirements and discount structures to prepare accurate and competitive quotes. The document also highlights potential policy considerations such as Prior Authorization and Step Therapy, which may influence product selection and reimbursement.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for Glaucoma Agents (Prostaglandin subclass) for the August 2026 P&T Committee Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Program (ADP) with non-FAMP discounts, and ADP with WAC discounts.

• BPA Appendix: Lists Glaucoma Agents (Prostaglandin subclass) with associated NDC numbers, strengths, dosage forms, and package sizes. It outlines formulary scenarios (Uniform Formulary, Non-Formulary) and indicates 'NO QUOTE' for specific scenarios, with a note to confirm intent if cells highlight red.
• ADP (non-FAMP Discount) Appendix: Details pricing and refund calculations based on non-FAMP (non-Federal Acquisition Regulation) prices. It includes columns for Non-FAMP Price, Additional Offered Refund, Current Annual Federal Ceiling Price (FCP), Standard Refund, and Total Calculated Retail Refund. It also specifies formulary scenarios (Tier 2, Tier 3) and requires confirmation if cells highlight red.
• ADP (WAC Discount) Appendix: Outlines pricing and refund calculations based on Wholesale Acquisition Cost (WAC). It includes columns for WAC Price, WAC Discount, and Total Calculated Retail Refund. Similar to the non-FAMP appendix, it specifies formulary scenarios (Tier 2, Tier 3) and requires confirmation if cells highlight red.
• General Notes: Applicable to all sections include class notes regarding P&T Committee review, potential Prior Authorization (PA), special reimbursement methods, and Step Therapy. Manufacturers are reminded to submit the Quote Review Checklist and executed signature pages. Pricing per unit of measure is consistent across package sizes for a given dosage form and strength.

This document is crucial for manufacturers of Glaucoma Agents (Prostaglandin subclass) who are interested in supplying these products. It provides the framework for submitting quotes, outlines the pricing structures (BPA, non-FAMP, WAC), specifies refund calculations, and details the deadlines for quote submission (June 29, 2026). Bidders must review the formulary scenarios and pricing requirements to determine their quoting strategy and ensure timely submission of all required documentation.

Form / Attachment / Pricing Sheet

This document provides Frequently Asked Questions (FAQ) regarding the Price Appendix, which is likely a spreadsheet or similar tool used for submitting pricing information for the opportunity. It clarifies how to use the appendix for different pricing scenarios (BPA, ADP non-FAMP Discount, ADP WAC Discount).

• BPA (Best Price Available): Instructions on filling out yellow cells, auto-population of data based on Package Size, and how a red highlight indicates a non-submission for a condition set. It also details auto-calculation of Price per Unit and how to request additional NDC tables if needed.
• ADP (non-FAMP Discount): Guidance on inputting non-FAMP price and Current Annual Federal Ceiling Price, with auto-population for subsequent rows. It explains the red highlight for a 0.0000% Additional offered refund and provides the formula for Total Calculated Refund.
• ADP (WAC Discount): Clarifies WAC is for products without a FCP (e.g., diabetic supplies). It details auto-population of WAC price and the meaning of a red highlight for a 0.0000% WAC Discount. It also explains the auto-calculation of Total Calculated Retail Refund per Package.
• General: For all sections, bidders are instructed to read Formulary Notes for P&T committee decision-making processes, fill only yellow cells, and contact POCs on the RFQ document for questions or to request more than 10 NDC tables.

This FAQ is crucial for bidders to correctly prepare and submit their pricing information using the Price Appendix. It clarifies data entry, calculation methods, and submission indicators, ensuring accurate and compliant proposals. Bidders should pay close attention to the specific instructions for each pricing type (BPA, ADP non-FAMP, ADP WAC) and the process for requesting additional tables if their needs exceed the default.

Other / Unclassified

This document outlines the process for the Department of Defense (DoD) formulary placement of newly FDA-approved innovator drugs. It references a Final Rule published in the Federal Register on July 27, 2015, which clarifies the process and gives the Pharmacy and Therapeutics (P&T) Committee up to 120 days to recommend tier placement.

• Drug Evaluation: The P&T Committee evaluates FDA-approved medications under specific biologic license applications (BLA) or new drug applications (NDA) types.
• Pending Status: Drugs approved by the FDA on or after August 26, 2015, will initially be assigned a pending status and treated as non-formulary.
• Solicitation for Pricing: The government will solicit Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (UF ADP) quotes for newly approved drugs. Manufacturers will have three solicitation windows to submit price concessions.
• Tier Designation: Drugs will be considered for Tier 1, Tier 2, Tier 3, and Tier 4/Not Covered designations based on clinical and cost-effectiveness information.
• Information Posting: Drugs to be reviewed will be posted on the health.mil/pandt page approximately 30 days before the quarterly meeting.
• Distribution and Pricing Agreements (DAPA): Pharmaceutical manufacturers are not obligated to obtain a DAPA, but information on establishing one can be obtained from the Defense Logistics Agency (DLA).
• MTF Access: Innovator drugs are generally designated as Tier 3 and not available at Military Treatment Facilities (MTFs) unless medical necessity criteria are met. If met, they may be available at a 2nd tier copay.
• Presentations: DoD will not entertain innovator drug clinical presentations due to the volume of newly approved drugs.